首页>
外文期刊>Prescrire international
>Empagliflozin (JARDIANCE°) in chronic heart failure - A second gliflozin in cardiology, without any demonstrated advantages
【24h】
Empagliflozin (JARDIANCE°) in chronic heart failure - A second gliflozin in cardiology, without any demonstrated advantages
展开▼
机译：Empagliflozin (JARDIANCE°) in chronic heart failure - A second gliflozin in cardiology, without any demonstrated advantages
In two placebo-controlled trials including a total of about 10 000 patients with chronic heart failure and either reduced or pre-served ventricular ejection fraction, empagliflozin reduced the frequency of hospitalisation for heart failure, with no evidence of reduced mortality. Given the absence of any comparison with other heartfailure drugs, empagliflozin has not been shown to represent a therapeutic advance. In particular, when the left ventricular ejection fraction is reduced, there is no evidence to suggest that empagliflozin offers any advantages over dapagliflozin.
展开▼
